QUOIN PHARMACEUTICALS LT-ADR (QNRX)
US74907L3006 - ADR
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.
Wondering what's happening in Thursday's pre-market session? Find an overview in this article.
Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study
Groundbreaking ‘Whole Body’ Study will be conducted by Dr. Amy Paller at Northwestern University Up to eight subjects will have QRX003 applied twice daily...
Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies
Clinical Data from First Subject Dosed Twice Daily with QRX003 in Open Label Study Is Positive at Mid-point of TestingSignificant Improvement in Skin...
These stocks are moving in today's after hours session
Top movers in Wednesday's after hours session
The trading volume of these stocks is deviating from the norm in today's session.
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results
Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant...
Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024
ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty...
Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO
Purchases Signal Leadership Confidence and Commitment to Company...
QNRX Stock Earnings: Quoin Pharmaceuticals Beats EPS for Q2 2024
QNRX stock results show that Quoin Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024.
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results
Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company Expands On-going Clinical Trials in Netherton...
Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome
Peeling Skin Syndrome is a rare autosomal disease with no approved treatment or cure Initial clinical site and pediatric patient identified in New...
Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024
ASHBURN, Va., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are a hot topic that traders are going to want to know about and we have all of the latest news on Tuesday morning!
Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference
ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty...
Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan...
QNRX Stock Earnings: Quoin Pharmaceuticals Misses EPS for Q1 2024
QNRX stock results show that Quoin Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results
FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome...
Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty...
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty...
TSLA Stock Alert: Tesla Plunges on Major China Slowdown
Tesla stock is falling on Tuesday as TSLA investors digest the latest delivery data from the EV company and a decrease in China.
Why Is GitLab (GTLB) Stock Down 22% Today?
GitLab stock is falling hard on Tuesday as investors in GTLB react to a lackluster guidance in the company's Q4 earnings report.
Why Is Quoin Pharmaceuticals (QNRX) Stock Down 50% Today?
Quoin Pharmaceuticals stock is falling on Tuesday after the company announced the pricing of QNRX shares in a public offering.